ZA200606870B - Oxadiazolone derivatives as PPAR delta agonists - Google Patents

Oxadiazolone derivatives as PPAR delta agonists Download PDF

Info

Publication number: ZA200606870B
Authority: ZA; South Africa
Prior art keywords: alkylen; formula; compounds; alkyl; bond
Prior art date: 2004-04-01

Application number

ZA200606870A

Other languages

English (en)

Inventor

Keil Stefanie

Glien Maike

Chandross Karen

Merrill Jean

Ronan Baptiste

Wendler Wolfgang

Goerlitzer Jochen

Daniel D Mcgarry

Bernardelli Patrick

Terrier Corinne

Original Assignee

Sanofi Aventis Pharma Deutschl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2006-08-15

Publication date

2008-04-30

2006-08-15 Application filed by Sanofi Aventis Pharma Deutschl filed Critical Sanofi Aventis Pharma Deutschl

2008-04-30 Publication of ZA200606870B publication Critical patent/ZA200606870B/en

Links

ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical class O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 title description 4
108010015181 PPAR delta Proteins 0.000 title description 3
239000000556 agonist Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 53
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 33
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
229910020008 S(O) Inorganic materials 0.000 claims description 13
229910052717 sulfur Inorganic materials 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 9
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims description 3
-1 O-phenyl Chemical group 0.000 claims description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 2
208000016192 Demyelinating disease Diseases 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims description 2
208000025966 Neurological disease Diseases 0.000 claims description 2
210000003169 central nervous system Anatomy 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims description 2
230000004770 neurodegeneration Effects 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
230000003959 neuroinflammation Effects 0.000 claims description 2
210000001428 peripheral nervous system Anatomy 0.000 claims description 2
208000027232 peripheral nervous system disease Diseases 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
206010022489 Insulin Resistance Diseases 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
230000004129 fatty acid metabolism Effects 0.000 claims 2
239000008103 glucose Substances 0.000 claims 2
208000032928 Dyslipidaemia Diseases 0.000 claims 1
208000001145 Metabolic Syndrome Diseases 0.000 claims 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
230000003178 anti-diabetic effect Effects 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
230000002349 favourable effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000002503 metabolic effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
230000000694 effects Effects 0.000 description 2
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
102000023984 PPAR alpha Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200606870A 2004-04-01 2006-08-15 Oxadiazolone derivatives as PPAR delta agonists ZA200606870B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04007879A EP1586573B1 (de)	2004-04-01	2004-04-01	Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika

Publications (1)

Publication Number	Publication Date
ZA200606870B true ZA200606870B (en)	2008-04-30

Family

ID=34924545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200606870A ZA200606870B (en)	2004-04-01	2006-08-15	Oxadiazolone derivatives as PPAR delta agonists

Country Status (37)

Country	Link
US (3)	US20070179191A1 (de)
EP (3)	EP1586573B1 (de)
JP (1)	JP2007530612A (de)
KR (1)	KR20060135857A (de)
CN (1)	CN100582104C (de)
AR (1)	AR050576A1 (de)
AT (1)	ATE435225T1 (de)
AU (1)	AU2005231916A1 (de)
BR (1)	BRPI0509517A (de)
CA (1)	CA2561627A1 (de)
CR (1)	CR8572A (de)
CY (1)	CY1109370T1 (de)
DE (2)	DE602004004631D1 (de)
DK (1)	DK1740583T3 (de)
DO (1)	DOP2005000051A (de)
EC (1)	ECSP066892A (de)
ES (1)	ES2329484T3 (de)
GT (1)	GT200500028A (de)
HR (1)	HRP20090493T1 (de)
IL (1)	IL178056A0 (de)
MA (1)	MA28495B1 (de)
MY (1)	MY142431A (de)
NO (1)	NO20064981L (de)
PA (1)	PA8628701A1 (de)
PE (1)	PE20060323A1 (de)
PL (1)	PL1740583T3 (de)
PT (1)	PT1740583E (de)
RS (1)	RS51186B (de)
RU (1)	RU2374243C2 (de)
SI (1)	SI1740583T1 (de)
SV (1)	SV2006002071A (de)
TN (1)	TNSN06317A1 (de)
TW (1)	TW200602342A (de)
UA (1)	UA84203C2 (de)
UY (1)	UY28837A1 (de)
WO (1)	WO2005097786A1 (de)
ZA (1)	ZA200606870B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20060017929A (ko) *	2004-08-04	2006-02-28	동화약품공업주식회사	티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
CA2624102A1 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
DE602006016830D1 (de)	2005-09-29	2010-10-21	Sanofi Aventis	Derivate von 2-aminthiazolen und 2-aminooxazolen, verfahren zu deren darstellung und deren verwendung als arzneimittel
WO2007039172A1 (en) *	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
KR20090066289A (ko)	2006-09-08	2009-06-23	로드아일랜드하스피틀	알코올 유발성 뇌 질환의 치료, 예방 및 역행
CA2663115C (en)	2006-09-08	2015-04-28	Rhode Island Hospital	Treatment, prevention, and reversal of alcohol-induced liver disease
EP1932843A1 (de) *	2006-12-14	2008-06-18	sanofi-aventis	Sulfonyl-Phenyl-2H-(1,2,4) Oxadiazol-5-one-Derivate, Verfahren zur Herstellung dafür und zur pharmazeutischen Verwendung damit
EP2288607B1 (de) *	2008-06-09	2014-09-24	Sanofi	Sulfonamide mit heterozyklen und einer oxadiazolon-kopfgruppe, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika
BRPI0914978A2 (pt) *	2008-06-09	2015-10-27	Sanofi Aventis	sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos
WO2009149819A1 (en) *	2008-06-09	2009-12-17	Sanofi-Aventis	Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
CN102202672A (zh)	2008-10-10	2011-09-28	达拉生物科学公司	使用穗霉素衍生物治疗或预防疼痛的方法
SMT202000257T1 (it) *	2008-10-10	2020-07-08	Vm Discovery Inc	Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
JP5546542B2 (ja) *	2009-08-05	2014-07-09	第一三共株式会社	アミド誘導体
WO2011016470A1 (ja) *	2009-08-05	2011-02-10	第一三共株式会社	スルホン誘導体
WO2015061481A1 (en)	2013-10-23	2015-04-30	Dara Biosciences, Inc.	Methods of treating liquid tumors using compositions comprising spicamycin derivatives
WO2021092279A1 (en) *	2019-11-06	2021-05-14	Board Of Regents, The University Of Texas System	Methods for the treatment of dysmyelinating/demyelinating diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5256680A (en)	1988-11-29	1993-10-26	Warner-Lambert Company	3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW222626B (de) *	1991-07-22	1994-04-21	Pfizer
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
US5641796A (en) *	1994-11-01	1997-06-24	Eli Lilly And Company	Oral hypoglycemic agents
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CZ220498A3 (cs)	1996-01-17	1998-11-11	Novo Nordisk A/S	Deriváty 1,2,4-thiadiazinu a 1,4-thiazinu, příprava a použití
JP3149958B2 (ja)	1996-08-30	2001-03-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―１誘導体
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DE69723869T2 (de)	1996-12-31	2004-04-22	Dr. Reddy's Laboratories Ltd.	Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
EP1000066A1 (de)	1997-07-16	2000-05-17	Novo Nordisk A/S	Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19845405C2 (de)	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de)	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
WO2000063208A1 (en)	1999-04-16	2000-10-26	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
IL145922A0 (en)	1999-04-28	2002-07-25	Aventis Pharma Gmbh	Di-aryl acid derivatives as ppar receptor ligands
PT1177176E (pt)	1999-04-28	2006-08-31	Aventis Pharma Gmbh	Derivados de acidos triarilicos como ligandos de receptores ppar.
CA2371271A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
CA2376919C (en)	1999-06-18	2008-11-04	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en)	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
US6413737B1 (en)	1999-07-09	2002-07-02	Cohesion Technologies, Inc.	Ecarin prothrombin protease and methods
DK1204654T3 (da)	1999-07-29	2003-11-17	Lilly Co Eli	Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
BR0013727A (pt)	1999-09-01	2002-05-07	Aventis Pharma Gmbh	Derivados de sulfonilcarboxamida, processo para sua preparação e seu uso como medicamento
TW200528436A (en)	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
ES2215769T3 (es)	1999-12-03	2004-10-16	Astrazeneca Ab	Forma cristalina de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico.
AU2001254763A1 (en)	2000-03-31	2001-10-08	Prosidion Limited	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
HUP0300475A3 (en)	2000-04-25	2004-10-28	Kyorin Seiyaku Kk	Novel stable crystal of thiazolidinedione derivative and process for producing the same
PT1277736E (pt)	2000-04-28	2007-10-12	Asahi Kasei Pharma Corp	Novos compostos bicíclicos
JP2004507456A (ja)	2000-05-11	2004-03-11	ブリストル−マイヤーズ　スクイブ　カンパニー	成長ホルモン分泌促進薬として有用なテトラヒドロイソキノリン類縁体
AU2001264977B2 (en)	2000-05-30	2005-04-14	Merck & Co., Inc.	Melanocortin receptor agonists
EP1294682B1 (de)	2000-06-09	2004-04-28	Aventis Pharma Deutschland GmbH	Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
HUP0401081A3 (en)	2000-12-21	2010-06-28	Sanofi Aventis Deutschland	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and their use
WO2002067912A2 (en)	2001-02-22	2002-09-06	Smithkline Beecham Corporation	Method for treating ppar gamma mediated diseases or conditions
DE10112768A1 (de)	2001-03-16	2002-09-19	Merck Patent Gmbh	Phenylderivate 3
GB0111523D0 (en)	2001-05-11	2001-07-04	Glaxo Group Ltd	Chemical compounds
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
JP4436129B2 (ja)	2001-08-31	2010-03-24	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
WO2003043997A1 (en) *	2001-11-15	2003-05-30	Eli Lilly And Company	Peroxisome proliferator activated receptor alpha agonists
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004094393A1 (en)	2003-04-01	2004-11-04	Eli Lilly And Company	Phospholipase inhibitors
US7595403B2 (en)	2003-04-01	2009-09-29	Eli Lilly And Company	Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
DE102004005172A1 (de)	2004-02-02	2005-08-18	Aventis Pharma Deutschland Gmbh	Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
WO2007039172A1 (en) *	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals

2004
- 2004-04-01 EP EP04007879A patent/EP1586573B1/de not_active Expired - Lifetime
- 2004-04-01 DE DE602004004631T patent/DE602004004631D1/de not_active Expired - Lifetime
2005
- 2005-02-17 GT GT200500028A patent/GT200500028A/es unknown
- 2005-03-19 EP EP09005458A patent/EP2083006A1/de not_active Withdrawn
- 2005-03-19 HR HR20090493T patent/HRP20090493T1/xx unknown
- 2005-03-19 RU RU2006138498/04A patent/RU2374243C2/ru not_active IP Right Cessation
- 2005-03-19 DK DK05716233T patent/DK1740583T3/da active
- 2005-03-19 CA CA002561627A patent/CA2561627A1/en not_active Abandoned
- 2005-03-19 JP JP2007505433A patent/JP2007530612A/ja not_active Abandoned
- 2005-03-19 CN CN200580010743A patent/CN100582104C/zh not_active Expired - Fee Related
- 2005-03-19 EP EP05716233A patent/EP1740583B1/de not_active Expired - Lifetime
- 2005-03-19 KR KR1020067020503A patent/KR20060135857A/ko not_active Ceased
- 2005-03-19 SI SI200530778T patent/SI1740583T1/sl unknown
- 2005-03-19 AU AU2005231916A patent/AU2005231916A1/en not_active Abandoned
- 2005-03-19 UA UAA200611486A patent/UA84203C2/ru unknown
- 2005-03-19 AT AT05716233T patent/ATE435225T1/de not_active IP Right Cessation
- 2005-03-19 PT PT05716233T patent/PT1740583E/pt unknown
- 2005-03-19 ES ES05716233T patent/ES2329484T3/es not_active Expired - Lifetime
- 2005-03-19 DE DE602005015204T patent/DE602005015204D1/de not_active Expired - Lifetime
- 2005-03-19 PL PL05716233T patent/PL1740583T3/pl unknown
- 2005-03-19 BR BRPI0509517-4A patent/BRPI0509517A/pt not_active IP Right Cessation
- 2005-03-19 WO PCT/EP2005/002950 patent/WO2005097786A1/en not_active Ceased
- 2005-03-19 RS RSP-2009/0391A patent/RS51186B/sr unknown
- 2005-03-22 PE PE2005000323A patent/PE20060323A1/es not_active Application Discontinuation
- 2005-03-30 DO DO2005000051A patent/DOP2005000051A/es unknown
- 2005-03-30 TW TW094109908A patent/TW200602342A/zh unknown
- 2005-03-30 AR ARP050101221A patent/AR050576A1/es not_active Application Discontinuation
- 2005-03-31 MY MYPI20051461A patent/MY142431A/en unknown
- 2005-04-01 SV SV2005002071A patent/SV2006002071A/es not_active Application Discontinuation
- 2005-04-01 PA PA20058628701A patent/PA8628701A1/es unknown
- 2005-04-01 UY UY28837A patent/UY28837A1/es unknown
2006
- 2006-08-15 ZA ZA200606870A patent/ZA200606870B/en unknown
- 2006-08-24 CR CR8572A patent/CR8572A/es not_active Application Discontinuation
- 2006-09-13 IL IL178056A patent/IL178056A0/en unknown
- 2006-09-26 US US11/535,266 patent/US20070179191A1/en not_active Abandoned
- 2006-09-29 EC EC2006006892A patent/ECSP066892A/es unknown
- 2006-09-29 TN TNP2006000317A patent/TNSN06317A1/en unknown
- 2006-09-29 MA MA29354A patent/MA28495B1/fr unknown
- 2006-10-31 NO NO20064981A patent/NO20064981L/no not_active Application Discontinuation
2008
- 2008-06-05 US US12/133,405 patent/US7709509B2/en not_active Expired - Fee Related
- 2008-06-05 US US12/133,408 patent/US20080262052A1/en not_active Abandoned
2009
- 2009-09-16 CY CY20091100958T patent/CY1109370T1/el unknown

Also Published As

Publication number	Publication date
PT1740583E (pt)	2009-09-16
ECSP066892A (es)	2006-11-24
CN100582104C (zh)	2010-01-20
BRPI0509517A (pt)	2007-09-11
KR20060135857A (ko)	2006-12-29
US20080262052A1 (en)	2008-10-23
CN1938300A (zh)	2007-03-28
EP1586573A1 (de)	2005-10-19
US20070179191A1 (en)	2007-08-02
CA2561627A1 (en)	2005-10-20
AU2005231916A1 (en)	2005-10-20
EP1586573B1 (de)	2007-02-07
TNSN06317A1 (en)	2007-12-03
JP2007530612A (ja)	2007-11-01
RS51186B (sr)	2010-10-31
EP2083006A1 (de)	2009-07-29
CY1109370T1 (el)	2014-07-02
MA28495B1 (fr)	2007-03-01
EP1740583A1 (de)	2007-01-10
HK1100408A1 (zh)	2007-09-21
DE602005015204D1 (de)	2009-08-13
HRP20090493T1 (hr)	2009-10-31
PE20060323A1 (es)	2006-03-31
AR050576A1 (es)	2006-11-08
MY142431A (en)	2010-11-30
DE602004004631D1 (de)	2007-03-22
SV2006002071A (es)	2006-01-30
RU2006138498A (ru)	2008-05-10
UY28837A1 (es)	2005-10-31
TW200602342A (en)	2006-01-16
CR8572A (es)	2007-12-04
SI1740583T1 (sl)	2009-12-31
RU2374243C2 (ru)	2009-11-27
US20080255212A1 (en)	2008-10-16
PL1740583T3 (pl)	2009-12-31
US7709509B2 (en)	2010-05-04
IL178056A0 (en)	2006-12-31
DK1740583T3 (da)	2009-10-19
ATE435225T1 (de)	2009-07-15
GT200500028A (es)	2006-06-09
NO20064981L (no)	2006-12-28
DOP2005000051A (es)	2005-12-15
PA8628701A1 (es)	2006-11-25
WO2005097786A1 (en)	2005-10-20
ES2329484T3 (es)	2009-11-26
UA84203C2 (en)	2008-09-25
EP1740583B1 (de)	2009-07-01

Publication	Publication Date	Title
EP2913326B1 (de)	2020-07-15	Neue modulatoren von sphingosinphosphatrezeptoren
US20050203119A1 (en)	2005-09-15	Dihydropyridine compounds for treating or preventing metabolic disorders
RU2339624C2 (ru)	2008-11-27	Производные аминоиндазолов и их применение в качестве ингибиторов киназ
CA2780433C (en)	2018-01-02	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
KR101186386B1 (ko)	2012-09-26	Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
KR20040025915A (ko)	2004-03-26	디펩티딜 펩티다아제 ｉｖ의 저해제를 이용한 2형당뇨병의 치료
TWI313265B (en)	2009-08-11	Novel bicyclic inhibitors of hormone sensitive lipase
JP5524853B2 (ja)	2014-06-18	肺疾患及び心臓血管疾患を治療するための置換されたベンゾアゾールｐｄｅ４阻害剤
RU2007142328A (ru)	2009-05-27	Производные тиоксантина в качестве ингибиторов миелопероксидазы
CA2616451C (en)	2015-01-20	Substituted benzyl derivatives as gsk-3 inhibitors
BG63487B1 (bg)	2002-03-29	Използване на хетероциклени съединения
EP1879887A2 (de)	2008-01-23	Npy antagonisten, herstellung und anwendung
RU99105567A (ru)	2001-01-20	Производные пропионовой кислоты и их использование
CA2488535A1 (en)	2003-12-31	Glucocorticoid receptor ligands for the treatment of metabolic disorders
RU2008116581A (ru)	2009-11-10	Сульфонамидные производные, как активаторы гликокиназы, применимые для лечения диабета типа 2
CN107847499A (zh)	2018-03-27	治疗神经退行性疾病的方法
JP2005526696A5 (de)	2006-01-05
EP3138834B1 (de)	2020-03-04	Cyclohexenderivat, herstellungsverfahren dafür und pharmazeutische zusammensetzung zur vorbeugung oder behandlung von stoffwechselkrankheiten damit als wirkstoff
IL183373A0 (en)	2007-09-20	3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2022251533A1 (en)	2022-12-01	Heteroaryl diamide ire1/xbp1s activators
RU2459824C2 (ru)	2012-08-27	Новые соединения для лечения психических расстройств, их получение и применение
CA2436083A1 (en)	2002-09-19	Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
US20070105836A1 (en)	2007-05-10	Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
JP2008214305A (ja)	2008-09-18	置換アミン誘導体及びこれを有効成分とする医薬組成物
US7560475B2 (en)	2009-07-14	Phenylacetic acid derivative, process for producing the same, and use